focus -WSS

focus

author：comprehensive 2025-08-31 20:50:36 - browse：21

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Dana Farber says 6 studies to be retracted and 31 corrected

WSS

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

South Korea throws huge K

Naloxone nonprofit donates 200,000 doses after FDA approval

Dana Farber says 6 studies to be retracted and 31 corrected

Wikipedia

focus

focus

Medicare details structure of new drug price negotiation program

CVS is on a mission to consolidate health care. Will it work?

Medical leaders decry Supreme Court decision on affirmative action

High breast density mammograms need follow

In Memoriam: Notable people who died in 2023

Emergent cuts jobs, executive role in business shake

Medicare details structure of new drug price negotiation program

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A biotech analyst on neuroscience, placebo effect, not over

hotspot

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

American woman, child freed after being kidnapped in Haiti last month

Printout prescription drug information shouldn’t go digital

Friends ask where James Watson's attitudes about race came from

FDA endorses new sterilization method for medical devices

How to use technology to prevent future drug shortages

Wikipedia

hotspot

explore

hotspot